Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Restasis
Biotech
Aurinia ditches would-be Restasis rival after phase 2/3 fail
Aurinia is abandoning the dry eye program after it failed to beat placebo at helping patients produce more tears in a phase 2/3 study.
Amirah Al Idrus
Nov 2, 2020 5:05pm
Aurinia poaches CEO Peter Greenleaf from Cerecor
Apr 12, 2019 10:49am
Aurinia posts mixed midphase data on would-be Restasis rival
Jan 22, 2019 8:52am
Tear Film Innovations raises $8.5M after dry eye device 510(k)
May 22, 2018 1:57pm
